Compare Nutanix Inc (NTNX) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nutanix Inc vs Vertex Pharmaceuticals Incorporated — how do they compare? Nutanix Inc trades at $67.39 (market cap $18.24B), while Vertex Pharmaceuticals Incorporated trades at $522.29 (market cap $134.06B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 7.3× Nutanix Inc's market cap. Which is the better fit depends on your goals.
| NTNX | VRTX | |
|---|---|---|
Market Cap | $18.24B | $134.06B |
Sector | Technology | Health |
52-Week High | $81.12 | $557.96 |
52-Week Low | $34.41 | $376.62 |
Enterprise Value | $17.40B | $128.18B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Nutanix (NTNX) trades at $67.49, down 0.84% on the day, but maintains a bullish technical outlook with strong support near $66. The company reported robust Q4 2026 earnings, beating EPS estimates with $0.60 versus $0.49 expected, and revenue growth continues to accelerate. Analyst sentiment is overwhelmingly positive with a consensus price target of $77.20 and no sell ratings among 32 analysts covering the stock.
The outlook remains favorable given consistent earnings beats and recognition in Gartner's Magic Quadrant. Key risks include high valuation multiples like EV/EBITDA of 50.5 and competitive pressures in cloud infrastructure. The stock offers upside to consensus targets but requires monitoring of execution against growth expectations.
Vertex Pharmaceuticals (VRTX) trades at $528.9, down 3.15% on the day, amid a mixed technical and fundamental backdrop. The stock shows a bullish moving average signal but neutral oscillators, with key support at $522. Fundamentally, 2025 revenue reached $12.0B with a strong net income margin of 35%, though recent quarterly EPS results have been mixed. The company recently completed the acquisition of Crinetics Pharmaceuticals, signaling growth ambitions.
The outlook remains positive given analyst consensus favoring a Buy rating (84%) and a $548.78 price target, implying upside. Key opportunities include revenue growth from new drug launches, while risks involve competitive pressures and earnings volatility. The stock's current valuation at a P/E of 30.8 requires sustained execution to justify further gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Nutanix Inc
Nutanix, Inc. is a global leader in cloud software and hyperconverged infrastructure (HCI) solutions. The company's platform converges computing, virtualization, and storage into a single, seamless software-defined solution, enabling private, hybrid, and multi-cloud environments. Nutanix helps organizations simplify data center operations, manage their applications across various cloud platforms, and reduce IT complexity, positioning it as a key enabler of modern hybrid cloud strategies.
Read more on NTNX →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
